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unexpected because immersion in buffered neutral for-
malin, their technique, fixes full kidneys poorly. Similar
limitations affect Randall’s autopsy study, and all other
studies that used autopsy material to determine morpho-
logical changes in the kidneys of stone formers.
Increased interstitial osteopontin need not connote cell
injury. Osteopontin has multiple functions, including bone
formation. Vascular calcifications in coronary disease and
uremia share characteristics with embryonic bone forma-
tion and repair including osteopontin expression. Inter-
stitial osteopontin in ICSF may be linked to osteoblast-like
activity of the papillary interstitial cells, a hypothesis
suggested since 1942.5
In contrast to brushite, cystine, and obesity bypass
stone formers, ICSF, as we define them, have Randall’s
plaque and no evidence of cell injury.6
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To the Editor: The paper1 shows a relevant comparison
between support vector machines versus artificial neural
network (ANN). We think that support vector machine is a
very effective and promising method. Nevertheless, we think
that a different ANN approach should be used. In our
opinion, the authors should better explain what they mean by
ANN. In fact, ANN is a wide family of different algorithms
and methods. We could suppose that the ANN used in the
work is a Multi-Layer-Perceptron with Backpropagation
algorithm. In any case, stating ‘support vector machine
outperformed ANN’ by testing only one kind of ANN seems
not appropriate.
Besides, the authors say ‘training and testing should be
performed more than once and test set performances
averaged out, to reduce the variance of the performance
estimate’.
It is well known that every training performed by an ANN
is unique, owing to many intrinsic characteristics, as, for
example, the randomly selected starting weights.2 Every
training has its own history and results. If we average out
these results, changing the test-set each time, we find a
medium value of a particular kind of ANN. It is a statistical
measure of different things. It could be more interesting to
train several ANNs, test them once, and take the best. There
are many ways to understand whether the training and
testing subsets have been chosen correctly. For example, a
third subset of the database can be used as a validation set.3
We suggest that different ANN approaches and further
tests should be carried out before asserting ‘support vector
machine outperformed ANN’.
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We try to elucidate the issues raised in the Letter by
Tonello1 with the following points:
1. In Dal Moro et al.2 we adhered to what is the widely
most accepted structure for artificial neural network
(ANN), the multi-layer, feed-forward ANN trained via
the back-prop algorithm; the depth and width of the
structure (number of layers and of nodes per layer),
along with other parameters (thresholds and starting
weights) were modified. It is known that such an ANN
can interpolate even discontinuous functions hence its
structure is quite general, especially for the considered
problem.
2. As for the training method, we again adhered to a
statistically sound technique: for each fixed combina-
tion of the above structure/parameters, we ran several
simulations and performed proper averages; this is
necessary because the training is non-deterministic,
hence performing it once would yield statistically
unreliable outputs, as strongly motivated in Dal Moro
et al.2
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3. As for the testing procedure, we indeed used datasets
non-overlapping with those upon which the training
was run; this is necessary to avoid unwanted biases.
Furthermore, as described in Dal Moro et al.2 we chose
a number of non-intersecting training/testing sets by
properly ‘shuffling’ the whole data set, and took
averages of the results, thus validating the model.
4. The above canonical procedure has been performed
also for the logistic regression and support vector
machine algorithms, modulo the differences in struc-
ture, in the entity and number of parameters
considered, and in the training scheme employed for
the particular methodology. The collection of results
are finally compared in Dal Moro et al.2 Figure 1.
In conclusion, although we understand that for special
problems the ANN may still yield reasonable results, we
argue that in general (from a theoretical perspective) and
in particular (for the considered case study) support vector
machine indeed outperform ANN.
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On Kidney International editorial
Evidence-based politics of salt and
blood pressure?
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To the Editor: Your editorial ‘Evidence-based politics of
salt and blood pressure’1 distorts both the scientific debate
among leading experts and contains significant factual errors
about the Salt Institute and our Data Quality Act challenge in
Salt Institute v. Leavitt.
You accuse the Salt Institute of having ‘invent(ed)
controversy’ on the question of whether the entire population
should be advised to reduce dietary salt. The Cochrane
Collaboration, the prestigious consortium of medical scien-
tists who invented and defined the practice of ‘evidence-
based medicine,’ rejects the evidence for a population
intervention.2 The current president of the International
Society of Hypertension rejects a ‘one size fits all’ approach.3
The founder of the American Society of Hypertension, a Time
magazine cover story subject for his seminal research, rejects
the idea that evidence justifies universal salt reduction.4 In
1998, investigative reporter Gary Taubes won the national
prize from the National Association of Science Writers for his
article in Science on ‘The (political) science of salt’5
chronicling National Heart, Lung and Blood Institute’s
efforts to quell scientific dissent. We did not ‘invent’ this
controversy among leading medical researchers.
You discuss our lawsuit, Salt Institute v. Leavitt, which
we brought jointly with the US Chamber of Commerce,
speculating disparagingly: ‘Their aim is probably to extract
data on a few patients and show that these few did not
respond to decreased salt intake with lowering blood
pressure.’ Utter nonsense. Our petition6 sought correction
of a statement by the National Heart, Lung and Blood
Institute that the DASH-Sodium study proved that every
American would benefit from lowering dietary salt. We
simply sought basic statistics, no patient data. Most scientists
would agree with us that the statistics we sought – blood
pressure means and standard deviations – are necessary to
interpret the findings, yet these have yet to be produced
5 years after the first report was published, despite a flood
of other published articles, one admitting that there is
no statistically significant association in six of the eight
subgroups.7 As the government intended to use the study to
support the Dietary Guidelines for Americans, the question is
clearly important. The government should meet the same
standards of scientific justification as private parties. And as
we have seen in the Vioxx debacle, even the higher private
sector standard may not be high enough.
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To the Editor: The editorial on the politics of salt and blood
pressure was exceptionally prescient in recognizing the
influence of a trade lobby, the Salt Institute, on policies
(Kidney Int 2006; 69: 1707–1708). In one regard, though, the
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